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Abstract
Bile acids are considered as extremely toxic at the high concentrations reached during bile duct obstruction, but each acid
displays variable cytotoxic properties. This study investigates how biliary obstruction and restoration of bile flow interferes
with urinary and circulating levels of 17 common bile acids. Bile acids (conjugated and unconjugated) were quantified by
liquid chromatography coupled with tandem mass spectrometry in serum and urine samples from 17 patients (8 men and 9
women) with biliary obstruction, before and after biliary stenting. Results were compared with serum concentrations
measured in 40 age- and sex-paired control donors (20 men and 20 women). The total circulating bile acid concentration
increases from 2.7 mM in control donors to 156.9 mM in untreated patients with biliary stenosis. Serum taurocholic and
glycocholic acids exhibit 304- and 241-fold accumulations in patients with biliary obstruction compared to controls. The
enrichment in chenodeoxycholic acid species reached a maximum of only 39-fold, while all secondary and 6a-hydroxylated
species –except taurolithocholic acids – were either unchanged or significantly reduced. Stenting was efficient in restoring
an almost normal circulating profile and in reducing urinary bile acids.
Conclusion: These results demonstrate that biliary obstruction affects differentially the circulating and/or urinary levels of the
various bile acids. The observation that the most drastically affected acids correspond to the less toxic species supports the
activation of self-protecting mechanisms aimed at limiting the inherent toxicity of bile acids in face of biliary obstruction.
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Introduction
Biliary stenosis caused by bile duct stones, chronic pancreatitis
or tumors, results in bile retention within the ducts and liver. Such
obstruction causes numerous disturbances in liver physiology,
particularly for bile acid synthesis, transport and metabolism [1,2].
Bile acids play essential roles in the control of cholesterol
homeostasis and dietary lipid absorption, but are cytotoxic at
elevated concentrations. Approximately 200 to 600 mg of bile
acids are synthesized daily and compensate for the loss of acids
eliminated in the bile and excreted in feces [3]. In humans, the
circulating bile acids mainly correspond to the primary cholic (CA)
and chenodeoxycholic acids (CDCA) (reviewed in Monte M.J.
et al. [4]). These acids are conjugated with taurine and glycine to
form amidated detergents [4]. Conjugated and unconjugated bile
acids sustain a strong enterohepatic recirculation, through which
they can be deconjugated in the intestine and converted into the
secondary deoxycholic (DCA) and lithocholic acids (LCA). Bile
acids reabsorbed in the intestine can then be further modified back
in the liver [4]. These modifications correspond to reconjugation
with taurine and glycine, or conversion of CDCA and LCA into
the 6ahydroxylated acids, hyocholic (HCA) and hyodeoxycholic
acids (HDCA), respectively [5,6,7].
It has already been known that biliary obstruction results in a
marked accumulation of intrahepatic bile acids, which is reflected
by a dramatic increase of the total circulating bile acid
concentration [2,3,8]. These natural detergents are generally
considered as cytotoxic at high concentrations (reviewed in
Hofmann A.F. [9]), and their accumulation in the cholestatic
liver contributes to the disease, notably by promoting apoptosis
and necrosis of hepatocytes [9]. However, bile acid toxicity is
generally associated with their amphiphilic properties [9], and the
balance between hydrophobic and hydrophilic characters differs
among the bile acid species [4]. Accordingly, the hydrophobic
DCA has been shown to cause more membrane damage than CA
and its conjugates [10,11], whereas DCA, CDCA and LCA have
stronger deleterious effects on cell viability and mitochondrial
functions than other bile acids [10,12,13].
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is currently limited by the fact that only the total circulating bileacid
concentration is generally determined, while the composition of this
pool is rarely investigated [2,3,8]. Similarly, whether the circulating
and urinary levels of all bile acid species are equally corrected when
bile flow is restored has only received little attention [2,14]. A
comprehensive analysis of the bile acid profile in serum and urine
would therefore be required to fully grasp the toxicological effects
associated with biliary obstruction and bile flow restoration. Using
liquid chromatography coupled with tandem mass spectrometry
(LC-MS/MS), 17 bile acid species were quantified in serum and
urine samples from 17 patients with biliary obstruction obtained
before and after biliary stenting. Furthermore, the pre- and post-
stenting serum concentrations of each acid were compared to data
from 40 age- and sex-matched non-cholestatic volunteers.
Results
Biliary stenosis causes an accumulation of circulating
conjugated bile acids
The serum profile of bile acids in the non-cholestatic population,
used as control in the present study, has been described previously
[15]. When compared to this control population, the serum bile acid
profile from patients with biliary obstruction exhibited dramatic
changes (Table 1). The total of bile acids increased 58-fold (from 2.7
to 156.9 mM (Figure 1A). This accumulation mainly reflected a
marked enrichment in total taurine- and glycine-conjugated species
(190- and 67-fold, respectively; Table 1). Because tauro-bile acids are
lower than glycine conjugates in non-cholestatic samples, their
proportion increased from 13 to 42% in non-treated stenosed patients
(Figure 1B). In parallel, the relative abundance of glycine conjugates
Table 1. Serum bile acid composition in non-cholestatic volunteers (A: control) and patients before (B) and after (C) biliary
stenting.
At oB Bt oC At oC
A: Control B: Pre-stenting C: Post-stenting Change Change Change
Bile acids Mean ± SEM Mean ± SEM Mean ± SEM p Value p Value p Value
CDCA 256.8656.3 84.4660.2 236.2662.1 Q:,0.01 q:,0.05 n.s.
TCDCA 120.2621.8 16,577.864,370.2 286.7653.3 q:,0.001 Q:,0.001 q:,0.01
GCDCA 771.56111.9 28,534.565,754.4 1,986.86590.4 q:,0.001 Q:,0.001 q:,0.01
CA 181.5683.1 173.36133.5 86.6639.4 n.s. n.s. n.s.
TCA 179.7647.0 54,486.9613,419.0 302.6682.0 q:,0.001 Q:,0.001 n.s.
GCA 233.0656.0 56,222.3615,714.0 460.46100.0 q:,0.001 Q:,0.001 q:,0.05
UDCA 137.6625.1 20.3611.3 1,085.66446.4 Q:,0.001 q:,0.001 n.s.
TUDCA 5.061.1 74.9622.4 97.6630.3 q:,0.001 n.s. q:,0.001
LCA 12.861.8 1.560.7 26.366.2 Q:,0.001 q:,0.001 n.s.
TLCA 23.463.6 11.661.8 13.862.6 n.s. n.s. n.s.
GLCA 16.364.1 10.562.1 46.7612.7 n.s. q:,0.01 q:,0.01
LCA-S 7.361.1 4.261.8 14.364.2 Q:,0.01 q:,0.01 n.s.
DCA 386.7666.0 20.7615.7 254.4699.1 Q:,0.001 q:,0.01 Q:,0.05
TDCA 44.9611.8 213.4670.9 43.2611.0 q:,0.001 Q:,0.01 n.s.
GDCA 246.2642.5 417.6690.9 225.9660.4 n.s. n.s. n.s.
HDCA 41.265.6 4.963.5 29.469.0 Q:,0.001 q:,0.01 Q:,0.05
HCA 4.560.7 13.766.3 4.260.8 n.s. n.s. n.s.
Total CDCA 1,148.56147.7 45,196.769,624.4 2,509.66647.7 q:,0.001 Q:,0.001 q:,0.01
Total CA 594.06114.0 110,882.0627,143.0 850.06163.0 q:,0.001 Q:,0.001 n.s.
Total DCA 677.86106.1 651.86151.9 523.66132.2 n.s. Q:,0.001 n.s.
Total LCA 59.766.9 27.864.1 101.2622.4 Q:,0.01 q:,0.001 n.s.
Total primary 1,743.06226.0 156,079.0633,461.0 3,359.06741.0 q:,0.001 Q:,0.001 q:,0.01
Total Secondary 737.66108.8 679.66154.5 624.86145.4 n.s. n.s. n.s.
Total 6a-Hydroxylated 45.665.7 18.767.5 33.668.9 Q:,0.001 q:,0.01 Q:,0.01
Total Free 1,021.16193.6 318.86199.9 1,722.76575.8 Q:,0.001 q:,0.001 n.s.
Total Glyco 1,267.06186.0 85,185.0618,501.0 2,719.96670.0 q:,0.001 Q:,0.001 q:,0.01
Total Tauro 373.2673.0 71,364.6617,253.0 744.06145.0 q:,0.001 Q:,0.001 q:,0.001
TOTAL 2,669.06316.0 156,873.0633,526.0 5,201.061,111.0 q:,0.001 Q:,0.001 q:,0.001
Bile acids were quantified from 100 mL of serum from 40 healthy subjects (20 R and 20 =) and 17 stenosed patients (8 = and 9 R) before and after an endoscopic
stenting of the bile duct. Bile acid levels are expressed in nM. P-values were determined by the Wilcoxon/Mann-Whitney rank-sum test; n.s.: not significant. CA, cholic
acid; CDCA, chenodeoxycholic acid; DCA, deoxycholic acid; GCDCA, glycochenodeoxycholic acid; GCA, glycocholic acid; GDCA, glycodeoxycholic acid; GLCA,
glycolithocholic acid; HCA, hyocholic acid; HDCA, hyodeoxycholic acid; LCA, lithocholic acid; LCA-S, LCA-sulfate; TCDCA, taurochenodeoxycholic acid; TCA, taurocholic
acid; TDCA, taurodeoxycholic acid; TLCA, taurolithocholic acid; TUDCA, tauroursodeoxycholic acid; UDCA, ursodeoxycholic acid; TOTAL, sum of all bile acids.
doi:10.1371/journal.pone.0022094.t001
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remarkable changes observed in this population were the 304- and
241-fold accumulation of TCA and GCA, respectively. As a result,
these 2 acids accounted for ,10% of the total bile acid concentration
in non-cholestatic samples, but represented 31 and 32% of bile acid
species in patients with obstruction, respectively (Figure 2).
On the other hand, the conjugated species of CDCA were also
found to accumulate in samples from pre-stenting patients (138-
and 37-fold increases in GCDCA and TCDCA levels, respectively;
Table 1). These changes in CA and CDCA species led to a highly
significant (p,0.001) accumulation of total primary acids (91-fold),
total CA (186-fold) and total CDCA (39-fold) (Table 1). Other
significantly increased species were TUDCA (15-fold) and TDCA
(4-fold), while circulating levels of TLCA, GCA, GDCA and HCA
were not significantly affected. Interestingly, unconjugated species
of primary acids either remained unchanged (CA) or were even
significantly reduced (CDCA). UDCA (85%; p,0.001), LCA
(88%; p,0.001), LCA-S (42%; p,0.01), DCA (94%; p,0.001)
and HDCA (88%; p,0.001) levels were also significantly reduced.
These observations demonstrate that biliary obstruction causes
a drastic accumulation of primary bile acid species, and
particularly of TCA and GCA. Consequently, the relative
abundance of the primary species increased from 66 to 99.5% in
sera from control donors and patients, respectively (Figure 3A). By
contrast, the relative abundance of secondary and 6a-hydroxyl-
ated acids was significantly reduced (Figure 3B and C).
Biliary stenting improves the circulating bile acid profile
in patients with biliary obstruction
Biliary stenting almost completely corrected the bile acid profile
abnormalities described above. In particular, TCA and GCA
levels felt from 54.5613.4 and 56.2615.7 to 0.360.08 and
0.560.1 mM, respectively (Table 1). Consequently, after stenting,
the relative abundance of these 2 species was significantly reduced
to percentages similar to those observed in non-cholestatic donors
(Figure 2). Post-stenting reductions were also observed for
GCDCA and TCDCA (93% and 98%, respectively), thus leading
to a strong reduction in total primary (97%), total taurine (99%)
and total glycine (97%) levels (Table 1 and Figure 1). Almost all
other species found to be altered in cholestatic samples underwent
a correction as observed in samples obtained after stenting.
Despite the striking changes observed, the serum concentrations of
some acids remained significantly different from control levels after
stenting (Table 1 and Figure 2). This was especially the case for
TCDCA, GCDCA, GCA, TUDCA, GLCA and DCA, which
remained higher in post-treatment samples as compared to non-
cholestatic volunteers. As a result, total circulating bile acids
remained 1.9-fold higher (Figure 1A) in post-treatment samples
relative to non-cholestatic controls, while similar significant
variations were also observed for total CDCA, total primary, as
well as total glycine- and total taurine-conjugated species (Table 1).
Except for the latter variations in absolute concentrations, the
relative proportions of taurine- and glycine conjugated species in
post-stenting sera were not significantly different from those
detected in non-cholestatic samples (Figure 1B&C). The same also
applies to the relative abundance of primary, secondary and 6a-
hydroxylated acids (Figures 3A–C).
Overall, these observations indicate that biliary stenting is
efficient at restoring an almost normal circulating bile acid profile.
Biliary stenting also affects the urinary bile acid profile in
stenosis patients
As for serum, the most abundant bile acid species in the urine
from stenosis patients corresponded to the amidated forms of CA
Figure 1. Serum levels of total bile acids (A) and relative abundance of taurine- (B) and glycine- (C) conjugated species in non-
cholestatic donors and patients with biliary obstruction before and after biliary stenting. Bile acids were quantified as indicated in the
‘‘Experimental Procedures’’ section. Concentrations (A) and relative abundance of tauro- (B) and glyco-bile acids (C) in biliary stenosis patients (17
donors) before and after stenting were compared to those from a non-cholestatic group (40 volunteers). A: Total bile acids: sum of all 17 species. B:
Percentage of taurine conjugates: sum of taurine-conjugated acids divided by the sum of all bile acids. C: Percentage of glycine conjugates: sum of
glycine-conjugated acids divided by the sum of all bile acids. Graphics represent the mean 6 SEM. P-values were determined by the Wilcoxon/Mann-
Whitney rank-sum test. **: p,0.01, ***:p,0.001. n.s.: not significant.
doi:10.1371/journal.pone.0022094.g001
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However, almost all acids were found at lower concentrations in
urine than in serum, with the notable exception of CA, HCA and
HDCA concentrations, which were in the same range in both
fluids (Tables 1&2).
Restoring bile flow with stenting also resulted in a significant
reduction of total urinary bile acids, which mainly reflected the
decrease in TCDCA, GCDCA, TCA and GCA concentrations,
respectively (Table 2). Urinary levels of other species such as
TUDCA, DCA and HDCA were also significantly altered by
stenting, but only to a lower extent (Table 2). The relative
abundance of primary, secondary and 6a-hydroxylated acids
followed a similar pattern as in serum, with a modest reduction of
primary acids (from 99.7 to 93%) and a more pronounced
induction of secondary and 6a-hydroxylated forms (Figures 3D–F).
These results indicate that biliary stenting also affects the
urinary elimination of bile acids.
Discussion
The present study provides the first comprehensive analysis of
the profiles of circulating and urinary bile acids during bile duct
obstruction and after restoration of bile flow via biliary stenting.
According to previous reports [2,8,14], a strong accumulation in
total circulating bile acids is observed in patients with biliary
stenosis. We also observed an almost complete restoration of the
bile acid profile in serum samples after stenting, while the same
treatment strongly reduced urinary bile acids. Of note, the
reduction in serum acids is close to values previously reported in
comparable extrahepatic cholestasis populations [2,14]. In addi-
tion to these original comparative analyses, an important novel
aspect of the current work is the species-specific manner in which
circulating and urinary acids are affected by both bile flow
interruption and restoration. Indeed, of the 17 acids quantified, 6
underwent a significant increase in concentration, 5 were not
significantly altered, while 6 were significantly reduced in sera
from biliary obstruction patients as compared to control samples
(Table 1). Most of the acids undergoing reductions in levels
corresponded to secondary and 6a-hydroxylated species, whereas
the sole primary acid within this group was CDCA. Interestingly,
the reduction in CDCA levels is in accordance with the previously
reported downregulation of the cytochrome P450 (CYP)7A1, the
rate-limiting bile acid synthesizing enzyme, in the liver of patients
with biliary obstruction [2]. This effect was suggested to be a
response of the liver to bile duct obstruction aimed at reducing the
production of toxic bile acids [2]. However, such an outcome
would be only partly reached since circulating levels of conjugated
primary acids were dramatically increased. The latter observation
indicates that a reduction in CYP7A1 expression is insufficient to
abolish the production of bile acids during biliary obstruction.
In addition to reducing CYP7A1, biliary obstruction also
upregulates CYP8B1 expression in the liver [2]. This gene encodes
sterol 12a-hydroxylase, a key branch in the bile biosynthetic
pathway which favors CA instead of CDCA formation, and thus
Figure 2. Relative abundance of taurine- (A) and glycine- (B) conjugated cholic acid in serum from non-cholestatic donors and
patients before and after biliary stenting. TCA and GCA were quantified as indicated in the ‘‘Experimental Procedures’’ section. Their relative
abundance was calculated relatively to the sum of all bile acids. Graphics represent the mean 6 SEM (nM). P-values were determined by the
Wilcoxon/Mann-Whitney rank-sum test. **: p,0.01, ***: p,0.001. n.s.: not significant.
doi:10.1371/journal.pone.0022094.g002
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increased from 0.70 in control samples to 2.05 in sera from biliary
obstruction patients in the current study. This increase mainly
reflects the differential behavior of serum CA and CDCA levels:
i.e. CDCA was significantly reduced, while CA remained almost
unchanged. A similar increase also occurred when considering the
total CA/total CDCA ratio (0.51 and 2.45 in control and
cholestatic samples, respectively). As expected, biliary stenting
was efficient in reducing these ratios. These results indicate that
the production of CA instead of CDCA is favored during biliary
obstruction and that restoring the bile flow reinstates the
preferential conversion of cholesterol into chenodeoxycholic acid
species. In addition to their synthesis, the relative abundance of
CA and CDCA species may also be affected by their urinary
elimination. In urine, both pre- and post-stenting levels of CA (free
or conjugated) are higher than those of CDCA (Table 2). These
results indicate that CA derivatives are more efficiently excreted in
urine than those of CDCA. However, the fact that the stenting
procedure had a more profound impact on CDCA suggests that
urinary elimination of CDCA and its conjugates improved during
biliary obstruction.
These differential variations in abundance of primary bile acid
species are thought to affect the cytotoxic properties of the total
bile acids. Indeed, CA presents a lower hydrophobicity and higher
critical micelle concentration than CDCA [13]. As a result, CA
and its conjugates display lower cytotoxicity at high concentration
(reviewed in Perez MJ and Briz O [13]). Thus, the preferential
accumulation of CA instead of CDCA species supports the
hypothesis that bile duct obstruction triggers an adaptive response
aimed at limiting bile acid cytotoxicity [13].
A strong increase in serum TCA levels occurs in serum from
stenosed patients (Table 1). Similar TCA accumulations were
previously observed in other cholestatic situations, such as
intrahepatic cholestasis of pregnancy [17], thus supporting the
possible role of TCA as a biomarker for altered biliary circulation
[17]. This TCA accumulation is representative of the stronger
increase of circulating levels of taurine-conjugated bile acids as
compared to that of glyco-bile acids. Such a difference may also
interfere with the toxicity of the serum bile acids since taurine
conjugates, which can activate cell survival and anti-apoptotic
pathways, are less toxic than their glycine counterparts
[18,19,20,21]. This is particularly the case for TUDCA
Figure 3. Relative abundance of primary (A & D), secondary (B & E) and 6a-hydroxylated (C & F) bile acids in serum (A–C) and urine
(D–F) from non-cholestatic donors and/or patients before and after biliary stenting. Bile acids were quantified as indicated in the
‘‘Experimental Procedures’’ section. The relative abundance (expressed as a percentage) of primary, secondary and 6a-hydroxylated bile acid species
was determined by adding up all unconjugated and/or conjugated species of CDCA+CA, LCA+DCA or HDCA+HCA, respectively, and by dividing the
result by the total bile acids. Graphics represent the mean 6 SEM (nM). P-values were determined by the rank sums Wilcoxon/Mann-Whitney test.
*: p,0.05, ***: p,0.001. n.s.: not significant.
doi:10.1371/journal.pone.0022094.g003
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sera.
In contrast to primary bile acids, total secondary species
remained at comparable levels in all serum samples, and their
relative abundance was therefore drastically reduced in both
serum and urine from pre-operative cholestatic patients (Figure 3).
Interestingly, circulating levels of various species, such as LCA,
LCA-S and DCA, were significantly reduced during biliary
obstruction as compared to controls (Table 1). These observations
are in accordance with the reported absence of LCA accumulation
in the liver of patients with obstructive jaundice [26]. More
importantly, secondary acids are indicators of the entero-hepatic
recirculation of bile acids since they are formed in the intestine via
the enzymatic dehydroxylation of primary acids catalyzed by
bacterial enzymes [4]. The reduction in serum LCA and DCA
levels is therefore a consequence of the strong impairment of the
entero-hepatic bile acid recirculation in biliary stenosis patients.
Surprisingly, circulating levels of TDCA, the dehydoxylated
metabolite of TCA, were significantly higher in cholestatic than
in control sera. A likely explanation for this unexpected
observation is that a small amount of TCA, which undergoes an
enormous accumulation in the liver sustains enzymatic or non-
enzymatic dehydroxylation in hepatic cells. On the other hand,
secondary acids such as LCA are hydrophobic molecules and
among the most toxic bile acids [10,27]. It is therefore remarkable
that biliary obstruction results in a strong decrease in the relative
abundance of these toxic species.
In conclusion, profiling circulating and urinary bile acids in
biliary stenosis patients before and after stenting procedures
reveals that in addition to the dramatic increase of their total
concentration in both fluids, each species is differentially affected.
Furthermore, the stronger accumulation of less toxic species
further supports the notion that biliary obstruction activates a
series of self-defense mechanisms aimed at protecting the organism
against the inherent toxicity of bile acids [2]. Finally, we also
showed that biliary stenting is efficient in restoring an almost
normal circulating bile acid profile.
Materials and Methods
Ethics Statement
This study was approved by the appropriate clinical study
review boards at the CHUQ Research Centre, Laval University
(‘‘Comite ´ d’e ´thique de la recherche Clinique du CHUL’’, Que ´bec, QC,
Canada: projects #95.05.14 and #97.05.14) and the Pomeranian
Medical University (Bioethics commission, Pomeranian Medical
University in Szczecin, Poland: resolution Nu BN-001/43/06). All
patients had signed a written consent form before each procedure.
Materials
Unconjugated and taurine and glycine-conjugated bile acids
were purchased from Steraloids (Newport, RI). Deuterated bile
acids (d4-CA, d4-CDCA, d4-LCA and d4-DCA) were purchased
from C/D/N Isotopes (Montre ´al, Canada). Protein assay reagents
were obtained from Bio-Rad Laboratories Inc. (Marnes-la-
Coquette, France). HPLC-grade solvents were from VWR Canlab
(Montre ´al, QC, Canada). Solid-phase extraction (SPE) columns
used were 60 mg/3 mL Strata-X 33 mm polymeric reversed-phase
from Phenomenex (Torrance, CA).
Non-cholestatic volunteers and patients with biliary
obstruction
Liver biochemistries from non-cholestatic volunteers (control)
and subjects with biliary obstruction before and after biliary
stenting are shown in Table 3.
Serum samples from non-cholestatic donors (20 men and 20
women) were selected within the participants to the Genetics of
Lipid Lowering Drugs and Diet Network (GOLDN) study who
were recruited exclusively at the Minnesota fields center
(Minneapolis, MN), a single-arm, uncontrolled, nonrandomized
intervention aimed at identifying genetic factors associated with
interindividual variability of the triglyceride response to high-fat
meals and fenofibrate [28,29,30,31]. Only participants who had
not taken lipid-lowering agents for at least 4 weeks before the
initial visit were included. Exclusion criteria were as reported [28],
Table 2. Urinary bile acid profile in cholestatic patients
before and after stenting procedure.
Pre-stenting Post-stenting
Bile acids Mean ± SEM Mean ± SEM
Change:p-
value
CDCA 15.3610.6 5.861.6 n.s.
TCDCA 3,396.663,316.7 30.2614.6 Q:,0.001
GCDCA 8,628.368,307.0 80.5631.8 Q:,0.01
CA 115.8652.9 117.5647.9 n.s.
TCA 7,361.965,295.1 234.66155.4 Q:,0.001
GCA 10,177.264,654.6 487.56254.4 Q:,0.001
UDCA 4.261.5 60.1629.9 n.s.
TUDCA 181.8655.9 49.5637.4 Q:,0.01
LCA BLD BLD n.s.
TLCA 0.760.7 BLD n.s.
GLCA 0.960.6 0.860.5 n.s.
LCA-S 8.563.4 22.9610.9 n.s.
DCA 2.961.1 11.262.5 q:,0.01
TDCA 7.763.1 3.962.7 n.s.
GDCA 45.2618.4 23.368.8 n.s.
HDCA 1.760.9 7.862.5 q:,0.05
HCA 5.364.5 1.060.8 n.s.
Total CDCA 12,040.2611,623.0 116.6647.0 Q:,0.01
Total CA 17,654.969,435.9 839.66411.5 Q:,0.001
Total DCA 55.8620.6 38.3611.9 n.s.
Total LCA 10.163.5 23.7611.1 n.s.
Total primary 29,695.0620,660.0 956.26446.0 Q:,0.001
Total Secondary 65.9622.2 62.0618.1 n.s.
Total 6a-Hydroxylated 6.965.2 8.963.0 n.s.
Total Free 145.2666.8 203.5657.2 n.s.
Total Glyco 18,851.6612,187.0 592.16286.0 Q:,0.001
Total Tauro 10,948.668,594.1 318.26206.5 Q:,0.001
TOTAL 29,953.9620,661.0 1,136.76492.0 Q:,0.01
Bile acids were quantified from 100 mL of urine from 17 stenosed patients (8 =
and 9 R) before and after an endoscopic stenting of the bile duct. Bile acid
levels are expressed in nM. P-values were determined by the Wilcoxon/Mann-
Whitney rank-sum test; n.s.: not significant. BLD, below the limit of detection.
CA, cholic acid; CDCA, chenodeoxycholic acid; DCA, deoxycholic acid; GCDCA,
glycochenodeoxycholic acid; GCA, glycocholic acid; GDCA, glycodeoxycholic
acid; GLCA, glycolithocholic acid; HCA, hyocholic acid; HDCA, hyodeoxycholic
acid; LCA, lithocholic acid; LCA-S, LCA-sulfate; TCDCA, taurochenodeoxycholic
acid; TCA, taurocholic acid; TDCA, taurodeoxycholic acid; TLCA, taurolithocholic
acid; TUDCA, tauroursodeoxycholic acid; UDCA, ursodeoxycholic acid; TOTAL,
sum of all bile acids.
doi:10.1371/journal.pone.0022094.t002
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enzymes (aspartate aminotransferase and alanine aminotransfer-
ase) [28]. As extensively described in Lai et al. [28], participants
took part in five visits. However, sera used in the present study
were drawn at the first visit, when patients were free of any drug
treatment or lipid challenge.
Seventeen patients (8 men and 9 women; mean age 64610
years) with clinical and biochemical features of cholestasis were
recruited. In all cases, dilatation of the biliary tree was first
confirmed with abdominal ultrasound. Final clinical diagnoses in
patients included were as follows: common bile duct stones, 8
patients; pancreatic tumor, 5 patients; bile duct tumor, 1 patient;
benign common bile duct stenosis, 1 patient and chronic
pancreatitis, 1 patient. The endoscopic retrograde cholangiopan-
creatography (ERCP) procedure involved placement of plastic 10F
stents which were removed or replaced at a median of 5 weeks
after initial procedure, depending on the diagnosis.
Bile acid measurements
Bile acid concentrations were determined using a HPLC-MS/
MS system with an electrospray interface, using a novel method
adapted from Ye et al. [32]. The modified method allows the
simultaneous evaluation of 17 species in the same sample
(Figure 1A). Solid-phase extraction (SPE) was initiated by adding
2 mL of a 0.1% (w/v) formic acid solution and 30 mL of internal
standards (i.e: the deuterated bile acids d4-CDCA, d4-CA, d4-
LCA and d4-DCA) to 100 mL of serum. The same treatment was
applied to analytical standards which were diluted (1:1) with
100 mL of adsorbed serum, and subsequently used to generate
calibration equations. SPE columns were conditioned with 1 mL
MeOH and 2 mL of 0.1% formic acid. Columns were successively
washed with 2 mL of H2O and 2 mL of H2O:MeOH (80:20)
containing 0.1% formic acid under negative pressure. Bile acids
were eluted with 2 mL of MeOH. Eluates were completely
evaporated at 45uC under N2 and reconstituted in 100 mLo f
H2O:MeOH (50:50) containing 5 mM ammonium acetate and
0.01% formic acid. Fifteen mL of sample or calibration standards
were then injected into the LC-MS/MS system.
A single LC method was used for the separation of the free,
taurine, glycine and sulfate conjugates of bile acids. The
chromatographic system consisted of an Alliance 2690 Separations
Module (Waters, Milford, MA). Analytes were separated using a
5063 mm Synergi Hydro-RP column (2.5-mm particles) (Phenom-
enex, Torrance, CA). The chromatographic conditions used were:
5 mM ammonium acetate-0.01% formic acid in water (solvent A),
5 mM ammonium acetate-0.01% formic acid in MeOH (solvent
B), and acetonitrile (solvent C) at a flow rate of 800 mL/min. The
chromatographic program was as follows: (i) initial conditions:
40% A: 55% B: 5% C for 4 min; (ii) a linear gradient to 80% B
was applied over the next 8 min; (iii) the column was flushed with
90% B for the next 2 min; and (iv) re-equilibration to the initial
conditions over the next 4 min. All analytes were quantified by
tandem mass spectrometry (MS/MS) using an API3200 LC/MS/
MS instrument (Applied Biosystems, Concord, ON, Canada). The
analytical run required only 15 min, and the lower limit of
detection varied from 2.2 (LCA-S) to 8.0 nM (TCDCA).
Data analysis
Baseline characteristics as well as bile acid concentrations were
evaluated as means 6 SEM for continuous variables. The total
bile acid concentration corresponds to the sum of the 17 bile acid
levels. The sums of glyco- and tauro-conjugates were calculated by
adding up the concentrations of conjugated CDCA, CA, DCA
and LCA. The sum of free (i.e. unconjugated) bile acids also
includes HDCA and HCA levels. Total levels of primary,
secondary and 6a-hydroxylated bile acid species were determined
by adding up all unconjugated and/or conjugated species of
CDCA+CA, LCA+DCA or HDCA+HCA, respectively. The
relative abundance of a given species or group of species was
calculated as its concentration divided by the total bile acid
concentration, and is expressed as a percentage of total bile acids.
Bile acid concentrations were not normally distributed according
to the Shapiro-Wilk test, and therefore, the Wilcoxon/Mann-
Whitney rank-sum test was used instead for statistical purposes.
Correlations were assessed by the Spearman’s rank correlation
coefficient using the JMP Statistical Discovery V7.0.1 program
(SAS Institute, Cary, NC).
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Table 3. Liver biochemistries of patients involved in the study.
Normal Non-cholestatic Stenosed patients Stenosed patients
Range Subjects Before stenting After stenting
AST (U/L) 5–43 29.4061.32 219.67636.12
&&& 33.3066.28***
ALT (U/L) 5–60 26.1361.99 290.17655.04
&&& 44.90612.03***
&
AP (U/L) 20–140 n.d. 715.236189.91 157.10623.73***
cGT (U/L) 5–80 n.d. 1154.586225.31 238.90691.74**
Total bilirubin (mg/dl) 0.1–1.2 0.5460.04 15.0661.65
&&& 1.6060.32***
&&&
Liver biochemistries were determined in 40 non-cholestatic subjects (20 R and 20 =) and 17 stenosed patients (8 = and 9 R) before and after an endoscopic stenting of
the bile duct. Values represent the mean 6 SEM. P-values were determined by the Wilcoxon/Mann-Whitney rank-sum test.
**: p,0.01 vs. before treatment,
***: p,0.001 vs. before treatment,
&: p,0.05 vs. non-cholestatic,
&&&: p,0.001 vs non-cholestatic. ALT: alanine aminotransferase; AST: aspartate aminotransferase; AP: alkaline phosphatase, cGT: c-glutamyl transpeptidase; n.d.: not
determined.
doi:10.1371/journal.pone.0022094.t003
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